This research finding should benefit the company’s Colaris test, which identifies genetic mutations in the MLH1, MSH2, MSH6, and PMS2 genes and assesses a person's risk of developing colorectal and ...

SALT LAKE CITY, Nov. 29, 2010 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today said results from a major health economics study in Cancer Prevention Research, a journal of the American ...

You know what’s better than being the first one on your block to know about the next up-and-coming unsigned band so you can say “I can knew them back in the day” when they become huge? Nothing is, ...

Myriad Genetics Announces Plan to Separate Into Two Independent Public Companies; The Spin-Off Would Create Two Well Capitalized, Highly Focused, Independent Public Companies SALT LAKE CITY, ...

Myriad Genetics ( MYGN) recently made a presentation at a conference, which concluded that proper diagnostic test for Lynch syndrome, a hereditary form of colon cancer, should include the PMS2 gene.